Collection of blood and tissue samples from patients with upper aerodigestive cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to collect and store biological specimens from patients with head and neck, lung, and gastrointestinal cancers who are undergoing treatments that may affect the immune system. The research focuses on understanding how different cancer therapies influence immune responses, identifying risk factors for side effects from immunotherapy, and characterizing molecular features related to treatment response. Participants will provide samples such as blood, tumor tissue, and other biological materials to facilitate these investigations. The ultimate goal is to enhance the design of new therapies and predictive tests for cancer treatments.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Subjects with a pathologically confirmed or clinically suspected upper aerodigestive malignancy who may be candidates for known or potentially immunomodulating treatments
* Ability to understand and willingness to sign a written informed consent document

Exclusion Criteria:

* Patients with known significant contraindications for venipuncture (e.g., hemoglobin \<8.5 g/dL) will be excluded from the blood collection component of the study
* Patients with known significant contraindications for biopsy (e.g., severe bleeding diathesis) will be excluded from the tissue biopsy component of the study
* Patients with known significant contraindications for bronchoscopy (e.g., airway concerns, significant cardiac disease) will be excluded from the bronchoscopy component of the study
* Unable or unwilling to read English and complete forms/questionnaires

Where it's running

• Johns Hopkins University
  Baltimore, Maryland, United States Recruiting

Study contacts

• Principal investigator: Valsamo Anagnostou, MD, PhD — Johns Hopkins University
• Study coordinator: Valsamo Anagnostou, MD, PhD
• Email: ThoracicCancerTrials@jhmi.edu
• Phone: 410-614-8948

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Blood extracellular vesicles to detect chemotherapy-related nerve damage.

  We will test whether tiny blood particles called extracellular vesicles can predict who will develop chemotherapy-induced peripheral neuropathy in adults receiving taxane, platinum, or antimitotic chemotherapy.

  Recruiting Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Milan · NCT07558447

• High-precision detection of leftover cancer using a liquid-biopsy platform (SHERLOCK)

  This project will test whether sensitive blood and other fluid tests for circulating tumor DNA can find leftover cancer (minimal residual disease) in adults treated with curative intent for breast, lung, melanoma, gynecologic, or genitourinary cancers.

  Recruiting University Health Network, Toronto · Toronto, Ontario · NCT07524114

• Using blood tests to assess early treatment response in cancer patients

  This study is testing if blood tests that look for cancer DNA can help doctors see how well treatment is working for patients with different types of solid tumors.

  Recruiting Washington University School of Medicine · St Louis, Missouri · NCT04354064

• Effects of Atezolizumab on Cancer Patients with Sensitive Tumor DNA or RNA

  This study is testing if atezolizumab can help cancer patients with certain tumor types that show they might respond well to the treatment.

  Recruiting Phase 2 British Columbia Cancer Agency · Vancouver, British Columbia and 1 other locations · NCT04273061

• Collecting tumor samples to improve cancer treatment matching

  This study is collecting tumor samples from patients with advanced cancer to see if analyzing their genes can help doctors find the best treatments for them.

  Recruiting at 2 sites University Health Network, Toronto · Hamilton, Ontario and 6 other locations · NCT02906943

• Does the time of day for PD-1/PD-L1 therapy affect response in NSCLC and HNSCC

  In people with advanced NSCLC or resectable head and neck cancer, this study tests whether receiving PD-1/PD-L1 therapy in the morning versus the afternoon changes treatment outcomes.

  Recruiting Phase 2 UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT07630168

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.